

# FIVE-MINUTE REFRESHER


## Glycaemic management of type 2 diabetes

Consultant **Dr Tahseen Chowdhury** presents an overview of treatment options for diabetes

*Dr Tahseen Chowdhury is a consultant in diabetes and metabolism at Barts Health NHS Trust*



Download a PDF in a larger format. Go to [pulsetoday.co.uk/refreshers](http://pulsetoday.co.uk/refreshers)



### DRUG DETAILS

<p><b>Detemir/Glargine</b></p> <ul style="list-style-type: none"> <li>Consider if patient needs assistance to give insulin</li> <li>Or has hypoglycaemia on human insulin</li> <li>Or needs twice-daily NPH</li> </ul>	<p><b>DPP-4 inhibitor</b></p> <ul style="list-style-type: none"> <li><b>sitagliptin 25-100mg per day, linagliptin 5mg per day</b></li> <li>Weight neutral</li> <li>Linagliptin useful in renal disease</li> <li>Use for six months and stop if ineffective</li> </ul>	<p><b>GLP-1 – exenatide</b></p> <ul style="list-style-type: none"> <li><b>5-10µg bd, liraglutide 0.6-1.2mg od, lixisenatide 10-20µg od, exenatide LAR 2mg weekly, dulaglutide 0.75-1.5mg weekly</b></li> <li>Suitable if BMI &lt;35 (33 in Asians) and there are obesity-related comorbidities, or occupational concerns with insulin</li> <li>Nausea, diarrhoea common</li> <li>Continue for more than six months if 11mmol/mol reduction in HbA1c and 3% weight loss</li> <li>GLP-1 plus insulin only to be used with specialist care and advice from a consultant-led MDT</li> </ul>	<p><b>Insulin</b></p> <ul style="list-style-type: none"> <li>On starting offer structured programme</li> <li>Start with NPH insulin once or twice daily</li> <li>Biphasic or NPH + short acting if HbA1c &gt;75mmol/mol</li> <li>Biphasic with short-acting insulin analogue if patient prefers injecting immediately before meal, or if hypos problematic or blood glucose rises after meals</li> </ul>	<p><b>Metformin 500-2,500mg per day</b></p> <ul style="list-style-type: none"> <li>Can be used in pre-diabetes, gestational diabetes, type 1 diabetes</li> <li>Stop if eGFR &lt;30, reduce if &lt;45</li> <li>Start slow, titrate, after meals</li> <li>Modified release if sustained release not tolerated</li> </ul>	<p><b>Pioglitazone 15-45mg per day</b></p> <ul style="list-style-type: none"> <li>Avoid with heart failure, bladder cancer</li> <li>Bone fracture reported</li> <li>Weight gain</li> <li>Oedema</li> </ul>	<p><b>SGLT2 inhibitor – canagliflozin 100-300mg, dapagliflozin 5-10mg per day, empagliflozin 10mg per day</b></p> <ul style="list-style-type: none"> <li>Consider dual or triple therapy or with insulin</li> <li>Can aid weight loss</li> </ul>	<ul style="list-style-type: none"> <li>UTI and thrush common</li> <li>Contraindicated in eGFR &lt;45</li> <li>Avoid with diuretics</li> <li>Use for six months and stop if ineffective</li> <li>Consider DKA if patient becomes acutely unwell</li> </ul>	<p><b>Sulfonylurea – gliclazide 40-320mg daily</b></p> <ul style="list-style-type: none"> <li>Effective, but care in elderly, especially with hypoglycaemia</li> <li>Can cause weight gain</li> </ul>
--	---	---	--	--	--	--	---	---

**\*Consider relaxing the target HbA1c on a case-by-case basis in:**

- People who are older or frail
- People with significant comorbidities such as cardiovascular disease or renal impairment